HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tillmann Taube Selected Research

BI 6727

5/2022Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
8/2021Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial.
1/2021Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
10/2019Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors.
2/2016Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
11/2015Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
8/2014Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tillmann Taube Research Topics

Disease

6Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
09/2006 - 06/2002
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/2022 - 11/2015
4Neoplasms (Cancer)
11/2020 - 09/2006
3Thrombocytopenia (Thrombopenia)
05/2022 - 02/2005
2Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
06/2012 - 02/2005
1Neutropenia
05/2022
1Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
05/2022
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
05/2022
1Leukopenia
11/2020
1Anemia
11/2020
1Leukemia
10/2019
1Disease Progression
02/2016
1Fatigue
02/2016
1Nausea
02/2016
1Fever (Fevers)
08/2014
1Infections
08/2014
1Multiple Myeloma
09/2006
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
09/2006
1Purpura
03/2006
1Hematologic Neoplasms (Hematological Malignancy)
05/2005
1Lymphatic Diseases
05/2005
1Residual Neoplasm
07/2003

Drug/Important Bio-Agent (IBA)

7BI 6727IBA
05/2022 - 08/2014
4Phosphotransferases (Kinase)IBA
05/2022 - 11/2015
3Pharmaceutical PreparationsIBA
05/2022 - 02/2016
3Rituximab (Mabthera)FDA Link
06/2012 - 02/2005
2Inosine Triphosphate (ITP)IBA
06/2012 - 02/2005
2InterleukinsIBA
04/2006 - 05/2005
1Azacitidine (5 Azacytidine)FDA Link
05/2022
1Cytarabine (Cytosar-U)FDA LinkGeneric
08/2021
1DecitabineFDA Link
01/2021
1Itraconazole (Sporanox)FDA LinkGeneric
11/2020
1pomalidomideIBA
09/2006
1Thalidomide (Thalomid)FDA Link
09/2006
1Caspase 3 (Caspase-3)IBA
09/2006
1Interleukin-8 (Interleukin 8)IBA
04/2006
1ChemokinesIBA
04/2006
1Chemokine ReceptorsIBA
04/2006
1Messenger RNA (mRNA)IBA
01/2006
1Protein Isoforms (Isoforms)IBA
05/2005
1Interleukin-10 (Interleukin 10)IBA
05/2005
1Biological ProductsIBA
05/2005
1Immunoglobulins (Immunoglobulin)IBA
07/2003
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
07/2003
1iodoHis(3)- neurokinin A (INKA)IBA
06/2002

Therapy/Procedure

2Therapeutics
08/2021 - 06/2012
1Drug Therapy (Chemotherapy)
08/2021
1Intravenous Infusions
02/2016